1,095 results on '"Von Minckwitz, Gunter"'
Search Results
52. Neoadjuvant treatment of breast cancer – Clinical and research perspective
53. Strategies for developing Ki67 as a useful biomarker in breast cancer
54. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group
55. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
56. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials
57. Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69)
58. Treatment with Trastuzumab Beyond Progression
59. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial
60. Chemotherapeutic Agents
61. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
62. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
63. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial
64. Operable Breast Cancer: Neoadjuvant Treatment (Methodology)
65. Medikamentöse Therapiestudien zur Behandlung des Mammakarzinoms in Deutschland
66. The Impact of Neoadjuvant Treatment on Surgical Options and Outcomes
67. Selecting the neoadjuvant treatment by molecular subtype: How to maximize the benefit?
68. Neoadjuvant Therapy: What are the Lessons so far?
69. Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer
70. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial
71. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy
72. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials
73. Impact of Multifocal or Multicentric Disease on Surgery and Locoregional, Distant and Overall Survival of 6,134 Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
74. Treatment of breast cancer during pregnancy: an observational study
75. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
76. Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer
77. Preventive therapy for breast cancer: a consensus statement
78. Lessons from the neoadjuvant setting on how best to choose adjuvant therapies
79. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review
80. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials
81. Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer
82. Surgical Outcome after Neoadjuvant Chemotherapy and Bevacizumab: Results from the GeparQuinto Study (GBG 44)
83. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial
84. RANK expression as a prognostic and predictive marker in breast cancer
85. Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy
86. Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: Results of a randomised trial (GABG-IV E-93) – The German Adjuvant Breast Cancer Group
87. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
88. Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients
89. A Randomized Phase 2 Study Comparing EC or CMF Versus Nab-Paclitaxel Plus Capecitabine as Adjuvant Chemotherapy for Nonfrail Elderly Patients With Moderate to High-Risk Early Breast Cancer (ICE II-GBG 52)
90. Accuracy of ultrasound for predicting pathologic response during neoadjuvant therapy for breast cancer
91. Docetaxel-related side effects and their management
92. Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades
93. Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study
94. Breast Cancer Mastectomy Trends Between 2006 and 2010: Association with Magnetic Resonance Imaging, Immediate Breast Reconstruction, and Hospital Volume
95. Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer
96. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
97. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
98. Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference
99. Neoadjuvant chemotherapy in breast cancer—insights from the German experience
100. Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.